Beckman Research Institute Of The City Of Hope

Beckman Research Institute Of The City of Hope, a nonprofit cancer and translational medicine research organization headquartered in Duarte, California, operates as a prime recipient on federal grants spanning cancer biology, immunology, diabetes, and precision medicine—not as a federal contractor. The institute does not hold federal contracts or IDVs and does not compete on GWACs, BPAs, or federal supply schedules; its entire federal footprint is grant-based, with 80 percent of recent awards held as prime recipient and 20 percent as sub-recipient on larger consortia and cooperative agreements.

The institute's research portfolio centers on investigator-initiated biomedical research funded predominantly through the National Institutes of Health. Recent representative work includes a $24.2 million Other Transaction Agreement from the National Cancer Institute for the ADAPT-5205-P Immuno-Biomap project to collect immunotherapy biomarkers in metastatic non-small-cell lung cancer (awarded May 2025, performance through May 2031); a $8.445 million project grant from the National Institute of Diabetes and Digestive and Kidney Diseases for circulating extracellular vesicles as biomarkers for early type 1 diabetes detection (May 2026 through April 2029); and a $2.486 million Cancer Treatment Research grant from the National Cancer Institute for mutational epidemiology of childhood acute lymphoblastic leukemia in California (September 2026 through August 2029). The institute also holds Defense Health Agency project grants—a $1.32 million award for targeting diabetes-associated radioresistance in prostate cancer (September 2025 through September 2029) and a $2.136 million award for developmental therapeutics targeting RALBP1 for castration-resistant prostate carcinoma (September 2025 through August 2028)—reflecting growing military medical research engagement alongside its NIH portfolio.

Funding concentration reflects NIH dominance. The National Cancer Institute leads by award count (304 awards, though with minimal combined potential value due to the typical scale of individual R01 and project grants), while the National Heart, Lung, and Blood Institute anchors the institute by dollars ($58.5 million combined potential value across 46 awards). The National Institute of Diabetes and Digestive and Kidney Diseases ranks third by potential value ($6 million across 76 awards). Department of Health and Human Services agencies (NIH and its constituent institutes) account for 74 percent of awards by count and 93 percent by combined potential value. The Defense Health Agency represents the second-largest funding agency, with 35 awards reflecting rising engagement in military medical research priorities including cancer immunotherapy, precision diagnostics, and quality-of-life outcomes in survivorship.

The institute functions as an embedded research enterprise within City of Hope, a nonprofit comprehensive cancer center. It operates no separate SCI-reportable federal service-contract portfolio of scale—five SCI records span FY2024–FY2025 (three as prime, two as named sub), totaling $473 thousand in reported invoiced revenue across 1.6 FTEs at median government-paid rates around $820/hr for genomic training services. This minimal SCI footprint reflects the grant-dominant business model: the institute delivers research through investigator-initiated mechanisms, cooperative agreements, and sub-awards on larger NIH and foundation grants, not recurring federal service contracts. Its 641 prime awards (80% of 805 total) are grants and cooperative agreements, not service procurements; its 164 sub-awards (20%) primarily reflect roles as sub-recipient on multisite NIH consortia and cooperative research networks. Recent activity shows stability with slight decline: 92 awards in 2024, 72 in 2025, 50 in 2026 (year-to-date). Eighty-seven awards face ultimate completion within the next twenty-four months, representing $1.4 million in recompete exposure across the research pipeline.

The institute's federal role is research performance and translation, not procurement or vendor support. Competitive intelligence and partnership opportunities lie in collaborative research arrangements (co-PI roles, sub-recipient positions on multisite grants), clinical-trial site management through Defense Health Agency and cancer-center cooperative agreements, and integration into NIH-funded research networks spanning precision oncology, immunotherapy, metabolic disease, and survivorship outcomes.